. Author manuscript; available in PMC: 2011 Dec 5.

Published in final edited form as: Hematol Oncol Clin North Am. 2011 Apr 22;25(3):557–ix. doi: 10.1016/j.hoc.2011.03.007

Table 2.

Phase II initial salvage therapy with TIP in advanced GCT

Reference	Drug doses (per cycle)	Selection Criteria	Evaluable	CR (%)	Additional Efficacy Data
Kondagunta et al ³⁹	Paclitaxel: 250 mg/m²	1^st line salvage in	46	32	susCR:
	Ifosfamide 6000 mg/m²	pts with		(70)	63%
	Cisplatin 100 mg/m²	favorable			2-year PFS
		features^a			65%
					2-year OS
					78%

Mead et al ⁴⁰	Paclitaxel: 175 mg/m²	1^st line salvage	43	13	1-year FFS
	Ifosfamide 5000 mg/m²	following failure		(31)	38%
	Cisplatin 100 mg/m²	to BEP			1-year OS
					70%

Mardiak et al ⁴¹	Paclitaxel: 175 mg/m²	1^st line salvage	17	7	2-year DFS
	Ifosfamide 6000 mg/m²	following failure		(41)	47%
	Cisplatin 100 mg/m²	to cisplatin-			2-year OS
		based regimens			64%

TIP, paclitaxel, ifosfamide, cisplatin; CR, complete response; susCR, sustained CR (median follow-up 69 months); PFS, progression-free survival; FFS, failure-free survival; OS, overall survival; DFS, disease-free survival, PR, partial response.

Must meet all the following: 1) gonadal primary site, 2) maximum 6 prior cycles of cisplatin 3) CR or PR with negative tumor markers following 1^st-line chemotherapy.